SUBCUT HF II (UK, 20 NHS sites, n=170) compared at-home subcutaneous furosemide via the Lasix ONYU patch-pump (80 mg over 5h) versus continued inpatient IV furosemide in patients admitted with HF-associated edema. At-home treatment yielded +4 days alive-and-out-of-hospital at 30 days (p<0.001) and reduced index hospitalization length by 5.5 days (p<0.001), sustained at 60 days, with equivalent safety. Lasix ONYU was FDA-approved October 2025; SUBCUT HF II provides the supporting RCT evidence. Direct implications for cardiology capacity planning.
Persistent congestion at discharge in patients hospitalised with heart failure (HF) is associated with worse outcomes; inpatient intravenous diuretic therapy is often prolonged because at-home parenteral options are limited. SUBCUT HF II evaluated whether a novel subcutaneous furosemide formulation (Lasix ONYU; 80 mg infused over 5 hours via patch-pump) administered at home is non-inferior — and operationally superior — to inpatient intravenous furosemide.
Investigator-sponsored, multicentre, open-label, randomised controlled trial across 20 UK National Health Service hospitals. 170 patients admitted for HF and requiring ongoing intravenous loop diuretic therapy were randomised 1:1 to (a) early discharge with at-home subcutaneous furosemide via Lasix ONYU or (b) continued inpatient intravenous furosemide. The primary endpoint was days alive and out of hospital (DAOH) at 30 days.
Patients randomised to at-home subcutaneous furosemide had 4 more days alive and out of hospital at 30 days than the inpatient comparator (p<0.001), with index-hospitalization length of stay reduced by 5.5 days (p<0.001). The DAOH benefit was sustained at 60 days. Safety and key secondary endpoints supported equivalence to in-hospital treatment.
At-home subcutaneous furosemide via Lasix ONYU is an effective and safe alternative to inpatient intravenous diuresis in patients with HF-associated edema, materially shortening hospitalization without compromising safety or efficacy. Lasix ONYU received FDA approval in October 2025; SUBCUT HF II provides the supporting randomised evidence. Results presented at Heart Failure 2026 (Barcelona, 9 May 2026). Peer-reviewed publication forthcoming.
